Journals / Eastern Journal of Medicine / 2016 / Cilt: 21 - Sayı: 1

Corresponding Author: Masashi Ohe, Department of General Medicine, Hokkaido Social Insurance Hospital

Pages
42–44
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The present case suggests that CAM treatment may be effective for RA.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Macrolide antibiotics provide not only anti-bacterial activity but also anti-inflammatory effects.
📊
Key Findings & Data:A 77-year-old woman suffering from RA, presented with exacerbation of arthralgia and articular swellings.
💡
Conclusion & Impact:The present case suggests that CAM treatment may be effective for RA.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Macrolide antibiotics provide not only anti-bacterial activity but also anti-inflammatory effects. We report herein a case of rheumatoid arthritis (RA) successfully treated using clarithromycin (CAM), a macrolide, in expectation of its antiinflammatory effects. A 77-year-old woman suffering from RA, presented with exacerbation of arthralgia and articular swellings. Because she was suffering from non-tuberculous mycobacterium and could not receive biological agents, CAM was successfully added to prednisolone and a nonsteroidal anti-inflammatory drug which had been administered before exacerbation. The present case suggests that CAM treatment may be effective for RA.

🔖

Cite This Article

BOHGAKİ, T., OHE, M. (2016). Corresponding Author: Masashi Ohe, Department of General Medicine, Hokkaido Social Insurance Hospital. Eastern Journal of Medicine, Cilt: 21 - Sayı: 1, 42–44. https://ajindex.com/articles/222618

References (9)

  1. Ogrendik M. Effects of clarithromycin in patients with active rheumatoid arthritis. Curr Med Res Opin 2007; 23: 515-522
  2. Saviola G, Abdi Ali L, Rossini P, et al. Clarithromycin in rheumatoid arthritis patients not responsive to disease-modifying antirheumatic drugs: an open, uncontrolled pilot study. Clin Exp Rheumatol 2002; 20: 373-378
  3. Saviola G, Abdi-Ali L, Campostrini L, et al. Clarithromycin in rheumatoid arthritis: the addition to methotrexate and low-dose methylprednisolone induces a significant additive value--a 24-month single-blind pilot study. Rheumatol Int 2013; 33: 2833-2838
  4. Tkalcevic VI, Bosnjak B, Pasalic I, et al. The antiinflammatory activity of clarithromycin inhibits TNFalpha production and prolongs survival following lipopolysaccharide administration in mice. Int J Antimicrob Agents 2008; 32: 195-196
  5. Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68: 954-960
  6. JungYO, Kim HA. Recent paradigm shifts in the diagnosis and treatment of rheumatoid arthritis. Korean J Intern Med 2012; 27: 378-387
  7. Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 2007; 17: 451-458
  8. Ogrendik M. Antibiotics for the treatment of rheumatoid arthritis. Int J Gen Med 2014; 7: 43- 47
  9. Rubin BK, Henke MO. Immunomodulatory activity and effectiveness of macrolides in chronic airway diseases. Chest 2004; 125: 70-78.